News

McNeil Nutritionals debuts Nectresse

BY Allison Cerra

FORT WASHINGTON, Pa. — The maker of Splenda has introduced a new zero-calorie sweetener.

McNeil Nutritionals said Nectresse, made from monk fruit extract, is 100% natural. As part of the product launch, the brand has tapped journalist Lisa Ling to serve as its spokeswoman. Ling is aiding the launch effort by spreading the story of Nectresse sweetener via a video testimonial. What’s more, Nectresses is encouraging consumers to share the video with their social networks, as well as request a free product sample by visiting Nectresse.com/free-sample.

"Recognizing that many consumers like to sweeten with natural ingredients, we are pleased to provide them with another option to enjoy all the sweet things they love, while reducing the calories from sugar in their diet," McNeil Nutritionals president Michael Conway said.

Nectresse sweetener is available in both single-serve packets (40 servings) and canisters (140 servings) at grocery stores, drug stores, supercenters and online for suggested retail prices of $3.99 and $6.99. respectively.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Blu Pharmaceuticals names Joe Dombrowski VP corporate development

BY Alaric DeArment

FRANKLIN, Ky. — Blu Pharmaceuticals has named Joe Dombrowski to the newly created position of VP corporate development, the company said.

Blu, based in Franklin, Ky., said Dombrowski will be responsible for strategic planning and business development, including mergers and acquisitions. Blu was founded in 2006.

Dombrowski previously worked as senior director for strategic planning and business development for Kremers Urban Pharmaceuticals.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Walgreens, ESI bury hatchet. Now what?

BY Jim Frederick

So Walgreens and Express Scripts have buried the hatchet. The question is, can the nation’s top pharmacy retailer regain the billions of dollars in contracted prescription revenues it ceded to its competitors after the two sides severed relations in January? And, given the way Walgreens has adjusted and reset its growth strategy since then, does it matter that much?

The two companies announced July 19, in a rather tersely worded statement, that they had “reached a multiyear pharmacy network agreement that includes rates and terms” that both sides could live with, although those terms were not disclosed. By (apparently) resolving a nearly year-long dispute over reimbursement terms with ESI, the new agreement allows Walgreens to smudge out the line in the sand it drew with the powerful PBM — a stand that smaller, less powerful chains and independents applauded.

The deal ends an ugly chapter in the history of the sometimes strained relationship between retail pharmacies and the pharmacy benefit management industry. But undoing the damage done to both sides will take time.

Left unsaid, at least explicitly, is the fact that there’s nothing exclusive about the new contract. Walgreens’ 7,907 drug stores will simply swim in a vast pool of more than 64,000 pharmacies nationwide participating in what both sides call “the broadest Express Scripts retail pharmacy network available to new and existing clients.”

That means Walgreens will have to compete the old fashioned way: it will have to fight, market by market, to win back the millions of customers who were forced to shift their prescription business to competitors like CVS/pharmacy, Walmart, Rite Aid and a slew of other mass merchant, supermarket and regional pharmacy operators. It’s what Drug Store News senior editor Michael Johnsen a href="http://drugstorenews.com/article/walgreens-and-esis-new-deal-september-will-be-about-battle-pharmacy-patient">calls a “return to block and tackle mode”.

To a weaker or less vertically integrated drug retailer, that might pose a huge threat to future growth and viability. But we’re talking about Walgreens. The chain can bring to bear a huge arsenal of competitive and strategic weapons, including massive economies of scale, a strong balance sheet and, not least, the capability of plugging numerous holes in the nation’s leaky health care bucket via a 50-state network of retail and clinical pharmacies, workplace health centers, specialty pharmacy services and retail clinics.

How will it play out long term? Let us know your prediction by clicking the link below.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?